Shrink Film,Shrink Wrap,Pvc Shrink Film,Heat Shrink Film Hebei Yintop Technology Co.ltd , https://www.yintopplasticfilm.com
This new drug code, TAK-390MR, was developed on the basis of Prevacid. The drug had two clinical trials. A total of 4,092 patients with erosive esophagitis participated. They were randomized and treated with 60/90 mg of TAK-390 MR or 30 mg of Prevacid daily. Both trials showed that the effect of 90 mg TAK-390MR was statistically superior to Prevacid, and that of 60 mg dose TAK-390 MR was also ideal, but did not reach a statistically significant level.
Among them, an experimental analysis showed that 93% of the subjects who used the 60-mg dose reached the treatment goal, 95% of the 90-mg dose group achieved this effect, and Prevacate was Only 92% of the patients in the test group achieved the above treatment goals. Another experimental result confirmed that in the effect of relieving the disease, the 60 mg and 90 mg TAK-390MR test groups were 6 percentage points higher than the Prevac test group.
Takeda plans to launch this new drug by the end of this year, and before the generic drug comes out, it will gradually allow patients who have previously used Prevacid to switch to new drugs. At present, Prevacic has annual sales of 2 billion U.S. dollars and the patent protection period of the drug will expire in November 2009.
Takeda Pharmaceutical Co., Ltd. said that its heartburn drug, which is in the research and development stage, is superior to Prevacid, the best-selling drug of its kind, in the treatment of esophagitis.